For example, the chemotherapeutic drug doxorubicin or the proteasome inhibitor bortezomib can trigger the upregulation of activating ligands for NKG2D receptor and DNAM-1 on multiple myeloma cells, thereby sensitizing them to NK cell-mediated lysis [53]. The gene discussed is CD226; the disease is plasma cell myeloma.